These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 6177596)

  • 1. [Simultaneous determination of zymogen activation time and zymogen level using chromogenic substrates in blood coagulation analysis].
    Svendsen L; Brogli M; Stocker K
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(1):150-6. PubMed ID: 6177596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experience with chromogenic substrates in studies of clotting and fibrinolytic systems.
    Chmielewska J; Latallo ZS
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(1):111-4. PubMed ID: 6177591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparin and low molecular weight heparins inhibit prothrombinase formation but not its activity in plasma.
    Ofosu FA; Lormeau JC; Craven S; Dewar L; Anvari N
    Thromb Haemost; 1994 Dec; 72(6):862-8. PubMed ID: 7740455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bothrojaracin, a proexosite I ligand, inhibits factor Va-accelerated prothrombin activation.
    Monteiro RQ; Zingali RB
    Thromb Haemost; 2002 Feb; 87(2):288-93. PubMed ID: 11858489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Monitoring anticoagulant treatment with the KEM-O-MAT 2HP autoanalyzer].
    Laharrague P; Leleu T; Poignot JL; Cambus JP; Biermé R
    Nouv Rev Fr Hematol (1978); 1983; 25(2):107-12. PubMed ID: 6866753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Use of chromogenic substrates for estimation of indicators of kallikrein-kinin and blood coagulation systems in blood plasma of patients with nephrotic syndrome].
    Baskova IP; Paskhina TS; Poliantseva LR; Iakubovskaia RI; Tiero A
    Vopr Med Khim; 1983; 29(5):96-9. PubMed ID: 6557709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
    Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in vitro investigation of prothrombin complex concentrates.
    Römisch J; Bonik K; Müller HG
    Semin Thromb Hemost; 1998; 24(2):175-81. PubMed ID: 9579640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Newer synthetic peptide substrates in coagulation testing: some practical considerations for automated methods.
    Svendsen LG; Fareed J; Walenga JM; Hoppensteadt D
    Semin Thromb Hemost; 1983 Oct; 9(4):250-62. PubMed ID: 6658459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineered recombinant factor VII Q217 variants with altered inhibitor specificities.
    Chang YJ; Hamaguchi N; Chang SC; Ruf W; Shen MC; Lin SW
    Biochemistry; 1999 Aug; 38(34):10940-8. PubMed ID: 10460149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of prothrombin activation by bothrojaracin, a C-type lectin from Bothrops jararaca venom.
    Monteiro RQ; Zingali RB
    Arch Biochem Biophys; 2000 Oct; 382(1):123-8. PubMed ID: 11051105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of antithrombin-dependent factor Xa inhibitors by prothrombin-induced clotting time.
    Harenberg J; Giese C; Hagedorn A; Traeger I; Fenyvesi T
    Semin Thromb Hemost; 2007 Jul; 33(5):503-7. PubMed ID: 17629847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiation of thrombin- and factor Xa-related amidolytic activity in plasma by means of a synthetic thrombin inhibitor.
    Svendsen L; Brogli M; Lindeberg G; Stocker K
    Thromb Res; 1984 Jun; 34(5):457-62. PubMed ID: 6377574
    [No Abstract]   [Full Text] [Related]  

  • 14. Determination of prothrombin by a micro-coagulation method.
    Kirchhof B; Schmale S; van de Loo J
    Haemostasis; 1983; 13(1):1-8. PubMed ID: 6840624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chromogenic substrate (S-2222) factor X assays in the follow-up of coumarin treated patients. No advantage over prothrombin time and/or thrombotest.
    Girolami A; Saggin L; Gazzetta R; Saltarin P
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1981; 108(4):610-6. PubMed ID: 6170557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential.
    Hemker HC; Wielders S; Kessels H; Béguin S
    Thromb Haemost; 1993 Oct; 70(4):617-24. PubMed ID: 7509511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New chromogenic substrates for thrombin with increased specificity.
    Kolde HJ; Eberle R; Heber H; Heimburger N
    Thromb Haemost; 1986 Oct; 56(2):155-9. PubMed ID: 2949389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prothrombin activation by immobilized thrombin].
    Strukova SM
    Biokhimiia; 1976 Apr; 41(4):643-9. PubMed ID: 1022290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of coagulation factors (II-VII-X) and kaolin partial thromboplastin time by the LKB 8600 Reaction Rate Analyser.
    Hjorth B; Kjaersgaard E
    Scand J Clin Lab Invest; 1977 Feb; 37(1):15-20. PubMed ID: 616022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of factor V during intrinsic and extrinsic coagulation. Inhibition by heparin, hirudin and D-Phe-Pro-Arg-Ch2Cl.
    Yang XJ; Blajchman MA; Craven S; Smith LM; Anvari N; Ofosu FA
    Biochem J; 1990 Dec; 272(2):399-406. PubMed ID: 2268268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.